SCYNEXIS, Inc.
NCM: SCYXLive Quote
📈 ZcoreAI Score
Our AI model analyzes SCYNEXIS, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get SCYX Z-Score →About SCYNEXIS, Inc.
Healthcare
Drug Manufacturers - Specialty & Generic
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
📊 Fundamental Analysis
SCYNEXIS, Inc. demonstrates a profit margin of -41.8%, which is below the sector average, suggesting competitive pressure.
The company recently reported 1808.5% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -16.5%, which indicates that capital utilization is currently under pressure.
At a current price of $1.00, SCYX currently sits at the 58th percentile of its 52-week range (Range: $0.56 - $1.31).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$44.66M
Trailing P/E
--
Forward P/E
-3.03
Beta (5Y)
1.15
52W High
$1.31
52W Low
$0.56
Avg Volume
610K
Day High
Day Low